Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology statement Journal Article
| Authors: | Hurria, A.; Levit, L. A.; Dale, W.; Mohile, S. G.; Muss, H. B.; Fehrenbacher, L.; Magnuson, A.; Lichtman, S. M.; Bruinooge, S. S.; Soto-Perez-de-Celis, E.; Tew, W. P.; Postow, M. A.; Cohen, H. J. |
| Article Title: | Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology statement |
| Abstract: | The American Society of Clinical Oncology (ASCO) convened a subcommittee to develop recommendations on improving the evidence base for treating older adults with cancer in response to a critical need identified by the Institute of Medicine. Older adults experience the majority of cancer diagnoses and deaths and make up the majority of cancer survivors. Older adults are also the fastest growing segment of the US population. However, the evidence base for treating this population is sparse, because older adults are underrepresented in clinical trials, and trials designed specifically for older adults are rare. The result is that clinicians have less evidence on how to treat older adults, who represent the majority of patients with cancer. Clinicians and patients are forced to extrapolate from trials conducted in younger, healthier populations when developing treatment plans. This has created a dearth of knowledge regarding the risk of toxicity in the average older patient and about key end points of importance to older adults. ASCO makes five recommendations to improve evidence generation in this population: (1) Use clinical trials to improve the evidence base for treating older adults with cancer, (2) leverage research designs and infrastructure for generating evidence on older adults with cancer, (3) increase US Food and Drug Administration authority to incentivize and require research involving older adults with cancer, (4) increase clinicians' recruitment of older adults with cancer to clinical trials, and (5) use journal policies to improve researchers' reporting on the age distribution and health risk profiles of research participants. (C) 2015 by American Society of Clinical Oncology |
| Keywords: | targeted therapy; solid tumors; chronic myelogenous leukemia; personalized medicine; mutations; breast-cancer; cell lung-cancer; metaanalysis; trials; next-generation |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 32 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-11-10 |
| Start Page: | 3826 |
| End Page: | 3833 |
| Language: | English |
| ACCESSION: | WOS:000366020100024 |
| DOI: | 10.1200/jco.2015.63.0319 |
| PROVIDER: | wos |
| PUBMED: | 26195697 |
| Notes: | Article -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work